{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:05:30Z","timestamp":1784930730465,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104838","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:27:18Z","timestamp":1781206038000},"page":"104838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+\/HER2+ breast cancer: An international real-world study"],"prefix":"10.1016","volume":"88","author":[{"given":"Tal","family":"Sella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-4049","authenticated-orcid":false,"given":"Frederieke","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-7837","authenticated-orcid":false,"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Venieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-711X","authenticated-orcid":false,"given":"Katarzyna","family":"Pogoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-630X","authenticated-orcid":false,"given":"Barbro","family":"Linderholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-238X","authenticated-orcid":false,"given":"Leonor","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5509-3937","authenticated-orcid":false,"given":"Natali","family":"Shirron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Maio D'Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawale","family":"Hajjaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5144-1285","authenticated-orcid":false,"given":"Erika","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Gonz\u00e1lez Cortijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-2410","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Rosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Constantinidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Demasure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areen","family":"Abu Remilah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greet","family":"Huygh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3935-7440","authenticated-orcid":false,"given":"Vivianne","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2638-4780","authenticated-orcid":false,"given":"Natacha","family":"Ruyssers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0841-194X","authenticated-orcid":false,"given":"Helena","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-850X","authenticated-orcid":false,"given":"Eurydice","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Cicin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Chiappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3354","authenticated-orcid":false,"given":"Mehmet","family":"Artac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgesah","family":"Kilictas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Baranseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vicente-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-3695","authenticated-orcid":false,"given":"Mustafa","family":"Atci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9502-8441","authenticated-orcid":false,"given":"Ayelet","family":"Shai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104838_bib1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-Positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104838_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104838_bib3","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO.23.02170","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2\u2013Positive breast cancer: 5-year results and correlative analyses from ATEMPT","volume":"42","author":"Tarantino","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104838_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-015-3426-z","article-title":"Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)","volume":"151","author":"Ruddy","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104838_bib5","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1016\/j.clbc.2025.05.002","article-title":"Real-world 5-Year outcomes of patients treated with the adjuvant paclitaxel trastuzumab (APT) regimen for stage I HER2-Positive early breast cancer: a retrospective international study","volume":"25","author":"Lobo-Martins","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104838_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41523-025-00846-4","article-title":"Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab","volume":"11","author":"Bonomi","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104838_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/fon-2021-0303","article-title":"Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience","volume":"18","author":"Diker","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2026.104838_bib8","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2016.72.0946","article-title":"Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials","volume":"35","author":"Saha","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104838_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104838_bib10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.mayocp.2016.08.002","article-title":"Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study","volume":"91","author":"Rocca","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.breast.2026.104838_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104669","article-title":"Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy","volume":"85","author":"Shai","year":"2026","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104838_bib12","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104838_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-021-06267-8","article-title":"Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial)","volume":"189","author":"Ruddy","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104838_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104696","article-title":"Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer","volume":"85","author":"Valenza","year":"2026","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104838_bib15","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term Follow-Up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104838_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.6004\/jnccn.2025.7080","article-title":"Ovarian function suppression in HR-Positive, HER2-Positive breast cancer: an exploratory analysis of the HERA trial","volume":"23","author":"Bae","year":"2025","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2026.104838_bib17","doi-asserted-by":"crossref","first-page":"GS1","DOI":"10.1158\/1557-3265.SABCS25-GS1-03","article-title":"Abstract GS1-03: adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive\/HER2-positive early breast cancer: an exploratory analysis from the ALTTO (BIG 2-06) trial","volume":"32","author":"Lambertini","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104838_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jnci\/djy094","article-title":"Adjuvant Anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-Positive early breast cancer patients","volume":"111","author":"Lambertini","year":"2019","journal-title":"J Natl Cancer Inst"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:29:19Z","timestamp":1784928559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"alternative-id":["S0960977626001487"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104838","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+\/HER2+ breast cancer: An international real-world study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104838"}}